2/12
07:17 am
exel
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/12
07:14 am
exel
Exelixis, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Exelixis, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/11
11:48 am
exel
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $46.00. They now have a "sector perform" rating on the stock.
Low
Report
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $46.00. They now have a "sector perform" rating on the stock.
2/11
10:24 am
exel
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Wells Fargo & Company from $30.00 to $35.00. They now have an "equal weight" rating on the stock.
Low
Report
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Wells Fargo & Company from $30.00 to $35.00. They now have an "equal weight" rating on the stock.
2/11
10:13 am
exel
Exelixis (NASDAQ:EXEL) was given a new $44.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Exelixis (NASDAQ:EXEL) was given a new $44.00 price target on by analysts at Stifel Nicolaus.
2/11
12:11 am
exel
Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
2/10
07:50 pm
exel
Exelixis Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Exelixis Q4 Earnings Call Highlights [Yahoo! Finance]
2/10
04:31 pm
exel
Exelixis: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Exelixis: Q4 Earnings Snapshot [Yahoo! Finance]
2/10
04:05 pm
exel
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
Medium
Report
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
2/10
10:51 am
exel
Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In [Yahoo! Finance]
Low
Report
Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In [Yahoo! Finance]
2/6
06:31 am
exel
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
2/4
07:17 am
exel
Exelixis (NASDAQ:EXEL) was given a new $44.00 price target on by analysts at Barclays PLC.
Low
Report
Exelixis (NASDAQ:EXEL) was given a new $44.00 price target on by analysts at Barclays PLC.
2/3
08:03 am
exel
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
Low
Report
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
2/2
10:03 am
exel
Exelixis (NASDAQ:EXEL) was given a new $49.00 price target on by analysts at Morgan Stanley.
Medium
Report
Exelixis (NASDAQ:EXEL) was given a new $49.00 price target on by analysts at Morgan Stanley.
2/2
08:12 am
exel
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer [Yahoo! Finance]
Low
Report
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer [Yahoo! Finance]
2/2
08:00 am
exel
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Medium
Report
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
2/2
07:18 am
exel
Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer [Yahoo! Finance]
2/1
08:26 pm
exel
Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential [Yahoo! Finance]
Low
Report
Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential [Yahoo! Finance]
2/1
10:33 am
exel
Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility [Yahoo! Finance]
2/1
07:53 am
exel
Is Exelixis (EXEL) Using Zanzalintinib To Redefine Its Post-Cabometyx Oncology Strategy? [Yahoo! Finance]
Low
Report
Is Exelixis (EXEL) Using Zanzalintinib To Redefine Its Post-Cabometyx Oncology Strategy? [Yahoo! Finance]
1/31
07:22 pm
exel
2 Stocks That Could Soar This Year [Yahoo! Finance]
Low
Report
2 Stocks That Could Soar This Year [Yahoo! Finance]
1/28
10:11 pm
exel
Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval [Seeking Alpha]
Low
Report
Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval [Seeking Alpha]
1/27
04:05 pm
exel
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Low
Report
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
1/27
08:04 am
exel
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a "buy" rating on the stock.
1/22
07:31 am
exel
Exelixis: High-Growth Oncology Name Trading At A Discount [Seeking Alpha]
Low
Report
Exelixis: High-Growth Oncology Name Trading At A Discount [Seeking Alpha]